BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/24/2024 9:24:56 AM | Browse: 135 | Download: 315
 |
Received |
|
2024-07-22 05:16 |
|
Peer-Review Started |
|
2024-07-22 05:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-08-15 05:52 |
|
Revised |
|
2024-08-26 16:58 |
|
Second Decision |
|
2024-09-09 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-09-09 06:58 |
|
Articles in Press |
|
2024-09-09 06:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2024-09-13 02:06 |
|
Typeset the Manuscript |
|
2024-09-19 07:23 |
|
Publish the Manuscript Online |
|
2024-09-24 03:15 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell & Tissue Engineering |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Innovative mesenchymal stem cell treatments for fatty liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Fei-Qiong Gao, Jia-Qi Zhu and Xu-Dong Feng |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xu-Dong Feng, MD, PhD, Doctor, Doctor, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Ningbo 315000, Zhejiang Province, China. xdfeng@zju.edu.cn |
| Key Words |
Alcohol-associated liver disease; Non-alcoholic fatty liver disease; Mesenchymal stem cells; Cell therapy; Inflammation |
| Core Tip |
Mesenchymal stem cells (MSCs) and their derivatives are a promising therapeutic approach for non-alcoholic fatty liver disease and alcohol-associated liver disease. MSCs, which come from diverse sources and are of low immunogenicity, can attenuate disease progression by modulating key molecular pathways, such as glycolipid metabolism, inflammation, oxidative stress, and fibrosis. In addition, derivatives of MSCs are also considered as a therapeutic strategy due to their ability to retain some of the beneficial effects of MSCs while reducing the risks inherent in cell therapy. However, further studies are needed to emphasize their important mechanistic role in liver injury repair function. Refining MSCs clinical application protocols using a well-defined mechanistic understanding may allow utilizing the full benefits of MSCs in the treatment of liver disease to enhance liver reparability and provide new hope for the treatment of non-alcoholic fatty liver disease and alcohol-associated liver disease. |
| Publish Date |
2024-09-24 03:15 |
| Citation |
<p>Gao FQ, Zhu JQ, Feng XD. Innovative mesenchymal stem cell treatments for fatty liver disease. <i>World J Stem Cells</i> 2024; 16(9): 846-853</p> |
| URL |
https://www.wjgnet.com/1948-0210/full/v16/i9/846.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v16.i9.846 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
